Frederick Lang

Frederick Lang is a resident physician specializing in internal medicine at Massachusetts General Hospital as of June 2024. With a strong background in clinical research, Frederick served as a scientific lead at Roivant Sciences, contributing to clinical trials focused on COVID-19 and sarcoidosis, and played a pivotal role in the development of gimsilumab and namilumab through the BREATHE clinical trial. Previous experience includes analyst positions at Axovant Gene Therapies, where Frederick improved the design of gene therapy studies, and Boost Healthcare Consulting, where hospital revenue recovery strategies were implemented. As a laboratory researcher at MD Anderson Cancer Center, Frederick led significant translational research on brain tumor therapies and developed algorithms for analyzing genomic data. Frederick earned a Doctor of Medicine degree from Columbia University Vagelos College of Physicians and Surgeons and a Bachelor of Science in Biology from Duke University.